Grant for High-Risk, High-Impact Brain Cancer Research Awarded to Ivy Center Investigator
November 10, 2022 09:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Dr. An-Chi Tien, Pharmacodynamics Core Leader of the Ivy Brain Tumor Center, is a recipient of the American Brain Tumor Association’s Discovery Grant,...
Jackie Ng shares her 23-year journey with meningioma in ‘Rising’
February 02, 2021 00:00 ET
|
Partridge Singapore
KUALA LUMPUR, Malaysia, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Life is unpredictable but, with grit and determination, anything is possible. Jackie Ng came to learn this firsthand during her 23-year...
NX Development Corp. (NXDC) Receives FDA Orphan-Drug Designation for Gleolan® (aminolevulinic acid HCl) in Meningioma
January 12, 2021 10:10 ET
|
NX Development Corp.
Lexington, KY, Jan. 12, 2021 (GLOBE NEWSWIRE) -- NX Development Corp. (NXDC), a life sciences company wholly owned by photonamic GmbH & Co. KG., today announced FDA orphan-drug designation for...
NX Development Corp. (NXDC) Launches Gleolan (aminolevulinic acid HCl) Meningioma Phase III Clinical Trial (NXDC-MEN-301)
November 17, 2020 14:12 ET
|
NX Development Corp.
Lexington, KY, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NX Development Corp (NXDC), a life sciences company wholly owned by photonamic GmbH & Co. KG., today announced the enrollment of the first...
National Brain Tumor Society and the Brain Science Foundation Partner to Fund Research for Most Common Brain Tumor Type
February 19, 2019 12:12 ET
|
National Brain Tumor Society
Boston, MA, Feb. 19, 2019 (GLOBE NEWSWIRE) -- National Brain Tumor Society (NBTS), a leading nonprofit dedicated to the brain tumor community in the United States, today announced a new partnership...